Generic Pravastatin Reaches Market With Teva ANDA Approval
This article was originally published in The Tan Sheet
Executive Summary
Watson is launching its authorized generic version of Bristol-Myers Squibb's Pravachol (pravastatin) following FDA approval April 24 of Teva's ANDA to market the 10 mg, 20 mg and 40 mg doses of the drug
You may also be interested in...
Generic Pravachol approval
FDA approves Barr Pharmaceuticals and subsidiary Pliva's generic version of Bristol-Meyers Squibb's cholesterol drug Pravachol Nov. 28. The Woodcliff Lake, N.J.-based company says it plans to launch 10 mg, 20 mg and 40 mg of the pravastatin product immediately. Barr also says Pliva received tentative approval for its pravastatin 80 mg and plans to launch it following the expiration of a competitor's 180-day generic drug exclusivity period. Watson announced in May its launch of a generic Pravachol following FDA approval of Teva's ANDA (1"The Tan Sheet" May 1, 2006, p. 12)...
Bayer Poised To “Seize Opportunities” After Rapid Integration Of Roche OTCs
Bayer will continue to pursue external as well as internal growth strategies for its OTC business following the rapid integration of Roche's OTC division
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC